Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0004-282x2012000100017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Treatments for Brain Tumors.
Vet Clin North Am Small Anim Pract
January 2025
Department of Small Animal Clinical Sciences, Veterinary and Comparative Neuro-oncology Laboratory, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, 205 Duckpond Drive, Blacksburg, VA 24061, USA. Electronic address:
Article Synopsis
- * Identifying common molecular and genetic pathways in dogs and humans has helped in discovering targeted therapies for these tumors.
- * Current treatment strategies involve advanced agents like nanocarriers and immunotherapies, but none are currently widely approved or available for clinical use.
Peptide-guided adaptor-CAR T-Cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors.
Oncoimmunology
October 2024
Department of Medical Oncology and Hematology, University Hospital Zürich (USZ) and University of Zürich (UZH), Comprehensive Cancer Center, Zürich, Switzerland.
Article Synopsis
- Somatostatin receptor type 2 (SSTR2) is commonly found on certain tumors, including gastro-entero-pancreatic neuroendocrine tumors and breast cancer, making it a target for therapy.
- Researchers developed a novel fluorescent-peptide antagonist, Octo-Fluo, that works with genetically engineered CAR T-cells to selectively trigger cell death in SSTR2-expressing cancer cells.
- In laboratory and animal studies, Octo-Fluo enhanced the effectiveness of AdFITC(E2)-CAR T-cells against tumors, but high concentrations of Octo-Fluo could reduce its effectiveness by saturating both the CAR and SSTR2, highlighting the importance of dosage for treatment success.
Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.
Turk J Med Sci
September 2024
Department of Pathology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkiye.
Background/aim: Meningiomas are the most common primary brain tumors of the central nervous system. Immunotherapy is a promising treatment method applied in many types of cancer. There is no standard and effective medical treatment to reduce recurrence and mortality in cases of incomplete resection of meningiomas and in high-grade cases.
View Article and Find Full Text PDFCurrent immunotherapy techniques in meningioma.
Expert Rev Anticancer Ther
October 2024
Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA.
Introduction: Although meningiomas are the most common primary brain tumor, there are limited treatment options for recurrent or aggressive lesions. Compared to other brain tumors, meningiomas may be uniquely amenable to immunotherapy by virtue of their location outside the blood-brain barrier.
Areas Covered: This review describes our current understanding of the immunology of the meninges, as well as immune cell infiltration and immune signaling in meningioma.
[Role of Pharmacotherapy in Treatment of Meningiomas].
No Shinkei Geka
July 2024
Department of Neurosurgery, Keio University School of Medicine.
Meningiomas constitute the most common primary tumors of the central nervous system. Despite maximum treatment, grade 2/3 meningiomas are associated with a high risk of recurrence. Stereotactic radiosurgery is the treatment of choice as adjuvant treatment for grade 2/3 meningiomas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!